Hepatitis C News and Research

Latest Hepatitis C News and Research

FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called chronic immune thrombocytopenic purpura (ITP). Promacta can be used in these children when they have not achieved an appropriate response using other ITP medicines or surgery to remove the spleen.

9 Oct 2015

Lonza, Benitec partner to develop scalable manufacturing process for AAV-based viral gene therapies

Lonza Houston, Inc., a global leader in biological, cell and viral gene therapy manufacturing, and Benitec Biopharma, a clinical stage biotechnology company commercializing a patented gene-silencing technology, DNA-directed RNA interference (ddRNAi), today announced that they have entered into a Manufacturing Services Agreement to develop a scalable manufacturing process for Benitec's ddRNAi-based, Adeno-Associated Virus (AAV)-delivered products intended for therapeutic use in humans.

7 Oct 2015

UT Southwestern announces launch of new health initiative

UT Southwestern Medical Center today announced the launch of "Call Out Cancer," a new health initiative designed to promote awareness, early detection, and prevention of all types of cancer.

6 Oct 2015

Understanding HCV disease progression rates among PWID

The Hepatitis C virus (HCV) infection is a chronic blood-borne viral infection that affects an estimated 160 million people, or 2-3% of the population world-wide. Alarmingly, chronic HCV infection accounts for one-quarter of the cases of cirrhosis and hepatocellular carcinoma (HCC). If HCV is left untreated, chronic liver disease will occur in 60-70% of the cases, cirrhosis in 5-20% of the cases, and 1-5% will die from decompensated cirrhosis or HCC.

6 Oct 2015

Generex agrees to acquire 51% equity interest in Hema Diagnostic Systems

Generex Biotechnology Corporation today announced that it has entered into a non-binding Letter of Intent (LOI) with Hema Diagnostic Systems, LLC (HDS), a Florida company that designs and manufactures proprietary infectious disease detection technologies.

30 Sep 2015

Real-time blood test based on DNA sequencing can rapidly diagnose Ebola and other acute infections

Using technical advances not yet developed when the 2014 Ebola outbreak began, UC San Francisco-led scientists completed a proof-of-principle study on a real-time blood test based on DNA sequencing that can be used to rapidly diagnose Ebola and other acute infections. The researchers said that the test can be used even where lab space and medical infrastructure are scarce.

From Oxford Nanopore Technologies 29 Sep 2015

Novel graphene oxide-based biosensor may speed up development of new drugs against HIV, cancer

Longing to find a cure for cancer, HIV and other yet incurable diseases, researchers have already tried out hundreds of drugs, each requiring preclinical and clinical testing with live subjects. How many chemical agents more to try? Moving at such rate, will we find the cure during our lifetime? One of the easiest ways to speed up the drug development process is to simply perform it outside of the living body (e.g., by watching the substances react with the smallest pieces of live tissue and thus quickly predicting the overall effect it will make to the body when inside).

23 Sep 2015

Vaginal silicone ring may protect women against HIV, herpes virus

Researchers at University Jean Monnet of Saint-Etienne, France have succeeded in developing a vaginal silicone ring that delivers molecules that act on both HIV and herpes virus. This research is presented at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC/ICC).

21 Sep 2015

Cattle virus found in human cancer cells

Evidence of exposure to bovine leukaemia virus (BLV) has been found in human breast cancer samples. This is the first suggestion of a possible link between infection with a leukaemia virus prevalent in cows and breast cancer in humans.

18 Sep 2015

Researchers establish link between bovine leukemia virus and human breast cancer

A new study by University of California, Berkeley, researchers establishes for the first time a link between infection with the bovine leukemia virus and human breast cancer.

16 Sep 2015

Benitec Biopharma initiates new site for ongoing Phase 1/2a TT-034 trial for hepatitis C

Benitec Biopharma Limited, a clinical-stage biotechnology company developing innovative therapeutics based on its gene-silencing technology, DNA-directed RNA interference (ddRNAi), is pleased to announce it has initiated a new site for its ongoing Phase 1/2a TT-034 trial at the Methodist Health System Clinical Research Institute in Dallas, Texas.

16 Sep 2015

ACP awarded $1,002,884 Cooperative Agreement to increase adult immunization rates in US

The American College of Physicians (ACP) was awarded a $1,002,884 Cooperative Agreement from the Centers for Disease Control and Prevention (CDC) to increase immunization rates in the United States.

16 Sep 2015

Sun Biomedical begins DMX-200 Phase II trial for treatment of chronic kidney disease

Sun Biomedical Limited today announced the first patient had been enrolled in a Phase II study of DMX-200, an innovative new treatment that combines two different drugs to treat chronic kidney disease.

15 Sep 2015

NYUCN researchers study sexual transmission of HCV among HIV-positive MSM

While sexual contact is not the most efficient means of hepatitis C (HCV) transmission, there have been several reports of outbreaks of sexually transmitted HCV in HIV-positive men who have sex with men (MSM). HCV infections are more likely to become persistent and to lead to progressive liver disease in people who are HIV-infected, even if they are receiving HIV treatment. Factors underlying these infections in HIV-positive MSM are only partially understood.

14 Sep 2015

Psychosis, hepatitis C infection are greatest risk factors for mortality in marginalized Vancouver residents

Marginalized residents of Vancouver's Downtown Eastside are dying at more than eight times the national average, and treatable conditions are the greatest risk factors for mortality, researchers at the University of British Columbia have found.

11 Sep 2015

DNDi announces successful completion of SCYX-7158 Phase I study for treatment of sleeping sickness

The Drugs for Neglected Diseases initiative (DNDi) has announced today at the 9th European Congress on Tropical Medicine and International Health in Basel, Switzerland, the successful completion of Phase I human clinical trials for SCYX-7158 (AN5568), the first oral drug candidate specifically developed from the earliest drug discovery stage to combat human African trypanosomiasis, or sleeping sickness, a deadly parasitic disease transmitted by the tsetse fly.

9 Sep 2015

DNDi unveils plans to better respond to the needs of neglected patients

After having built the world's largest drug development pipeline for the most neglected diseases, the Drugs for Neglected Diseases initiative (DNDi) has unveiled plans for a more flexible, dynamic portfolio approach, integrating various operating models to better respond to the needs of patients, notably in low- and middle-income countries. The plan also paves the way for new diseases to be taken up in DNDi's portfolio.

9 Sep 2015

HIV prevention program undergoes “real world” evaluation

A programme that provides pre-exposure prophylaxis (PrEP) to prevent HIV infection among sexually active gay men has not seen one case of HIV infection since it began in 2012, according to the first “real world” evaluation of the regimen at Kaiser Permanente San Francisco Medical Center.

4 Sep 2015

Penn researchers identify viral products that trigger immune response against RSV infection

Almost all human beings are exposed to the respiratory syncytial virus, or RSV, before their second birthdays. For most, the symptoms mimic those of the common cold: runny nose, coughing, sneezing, fever.

4 Sep 2015

HBV DNA levels guide antiviral treatment in chemotherapy setting

Pretreatment levels of hepatitis B virus DNA could inform the withdrawal of pre-emptive antiviral therapy in chronic HBV patients undergoing cytotoxic chemotherapy for cancer, indicate research findings published in Digestive Diseases and Sciences.

3 Sep 2015

Hepatitis C News and Research

Latest Hepatitis C News and Research

FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

Lonza, Benitec partner to develop scalable manufacturing process for AAV-based viral gene therapies

UT Southwestern announces launch of new health initiative

Understanding HCV disease progression rates among PWID

Generex agrees to acquire 51% equity interest in Hema Diagnostic Systems

Real-time blood test based on DNA sequencing can rapidly diagnose Ebola and other acute infections

Novel graphene oxide-based biosensor may speed up development of new drugs against HIV, cancer

Vaginal silicone ring may protect women against HIV, herpes virus

Cattle virus found in human cancer cells

Researchers establish link between bovine leukemia virus and human breast cancer

Benitec Biopharma initiates new site for ongoing Phase 1/2a TT-034 trial for hepatitis C

ACP awarded $1,002,884 Cooperative Agreement to increase adult immunization rates in US

Sun Biomedical begins DMX-200 Phase II trial for treatment of chronic kidney disease

NYUCN researchers study sexual transmission of HCV among HIV-positive MSM

Psychosis, hepatitis C infection are greatest risk factors for mortality in marginalized Vancouver residents

DNDi announces successful completion of SCYX-7158 Phase I study for treatment of sleeping sickness

DNDi unveils plans to better respond to the needs of neglected patients

HIV prevention program undergoes “real world” evaluation

Penn researchers identify viral products that trigger immune response against RSV infection

HBV DNA levels guide antiviral treatment in chemotherapy setting

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Hepatitis C News and Research

Latest Hepatitis C News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in